Barrier Therapeutics Misled Over Clinical Studies, Suit Says

Law360, New York (October 19, 2005, 12:00 AM EDT) -- Barrier Therapeutics Inc. misled investors about the success of its clinical-stage biopharmaceuticals, according to a complaint filed by investors in federal court Friday.

The class action was filed in the U.S. District Court for the District of New Jersey for purchasers of Barrier’s securities between April 29, 2004 and June 29, 2005.

The suit alleged two much-anticipated products were used to attract investors’ cash, despite dire warnings from the U.S. Food and Drug Administration.

Named in the complaint with Barrier are the company’s founder and chief...
To view the full article, register now.